Navigation Links
DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Date:10/26/2009

CUPERTINO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, October 29, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR®, TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
6. Select Medical Holdings Corporation Announces Exercise of Underwriters Option to Purchase Additional Shares
7. Digirad Corporation to Present at BIOCOM 4th Annual Investor Conference
8. Mirixa Corporation Announces MirixaEdge(SM)
9. WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders
10. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
(Date:7/5/2017)... company of over 2,000 employees and a leader in environmental and life science ... their position as the top American owned and operated environmental testing firm in ... ... ... , enhances Pace Analytical,s capability as an innovative full service provider in ...
(Date:6/30/2017)... 2017 In vitro diagnostics market firm Kalorama ... at least ten diagnostic companies have successfully completed financings.  ... and a loan facility.  The size of these financings ... Kalorama Information provides a monthly IVD Market Trends ... Center. "Diagnostics ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a leading provider of ... Senior Medical Center as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate ... Chief Medical Officer of Ambulatory Services for the UVA Health System, brings 30 years ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing homes, ... designed to accommodate patients with a wide range of ailments or special needs, but ... invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many uses, ...
(Date:7/20/2017)... ... 20, 2017 , ... Vixiar Medical, Inc. , a ... for monitoring cardiopulmonary diseases, announced today that it has raised seed round financing ... and fund final engineering and initial production of the Company’s first product, Indicor™, ...
(Date:7/20/2017)... Wisconsin (PRWEB) , ... July 20, 2017 , ... ... of two products that further expand its existing adherence automation lines. The ATP® ... that mirror the advanced technology of TCG’s standard products, but at a size ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch ... of - living - adjustment (COLA) is a bad deal for older and disabled ... price index (CPI) would grow even more slowly than the conventional one that is ...
Breaking Medicine News(10 mins):